[{"address1": "332 Encinitas Boulevard", "address2": "Suite 102", "city": "Encinitas", "state": "CA", "zip": "92024", "country": "United States", "phone": "858 224 9600", "website": "https://www.kiorapharma.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, engages in the development and commercialization of therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 2 clinical trials indicated for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. The company is also developing KIO-104, a non-steroidal, immuno-modulatory, small-molecule inhibitor of dihydroorotate dehydrogenase, currently under phase 1b/2a study for the treatment of posterior non-infectious uveitis, as well as under pre-clinical development for the treatment of proliferative vitreoretinopathy; KIO-101, an eye drop for the treatment of ocular presentation of rheumatoid arthritis; and KIO-201, an eye drop for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. It has commercialization agreement with 4SC Discovery GmbH, for KIO-101; and collaboration agreement with Th\u00e9a Open Innovation for the development KIO-301. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.", "fullTimeEmployees": 12, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian M. Strem Ph.D.", "age": 43, "title": "President, CEO & Director", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 586000, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Tosca CPA", "age": 43, "title": "Chief Financial Officer", "yearBorn": 1980, "fiscalYear": 2023, "totalPay": 324479, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Eric J. Daniels M.B.A., M.D.", "age": 49, "title": "Chief Development Officer", "yearBorn": 1974, "fiscalYear": 2023, "totalPay": 456163, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Stefan  Sperl Ph.D.", "title": "Executive Vice President of CMC & Operations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.63, "open": 4.63, "dayLow": 4.4601, "dayHigh": 4.7786, "regularMarketPreviousClose": 4.63, "regularMarketOpen": 4.63, "regularMarketDayLow": 4.4601, "regularMarketDayHigh": 4.7786, "beta": -0.229, "forwardPE": -1.8210117, "volume": 28492, "regularMarketVolume": 28492, "averageVolume": 34045, "averageVolume10days": 35600, "averageDailyVolume10Day": 35600, "bid": 3.35, "ask": 5.82, "bidSize": 200, "askSize": 200, "marketCap": 13653244, "fiftyTwoWeekLow": 3.6, "fiftyTwoWeekHigh": 8.982, "priceToSalesTrailing12Months": 0.85332775, "fiftyDayAverage": 4.47502, "twoHundredDayAverage": 5.077, "currency": "USD", "enterpriseValue": -17528806, "profitMargins": 0.17548999, "floatShares": 1451092, "sharesOutstanding": 2917360, "sharesShort": 17963, "sharesShortPriorMonth": 36216, "sharesShortPreviousMonthDate": 1718323200, "dateShortInterest": 1721001600, "sharesPercentSharesOut": 0.0062, "heldPercentInsiders": 0.02029, "heldPercentInstitutions": 0.49245998, "shortRatio": 0.44, "shortPercentOfFloat": 0.0062, "impliedSharesOutstanding": 2917360, "bookValue": 11.964, "priceToBook": 0.3911735, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1711843200, "netIncomeToCommon": 2276862, "trailingEps": -11.79, "forwardEps": -2.57, "lastSplitFactor": "1:9", "lastSplitDate": 1718064000, "enterpriseToRevenue": -1.096, "enterpriseToEbitda": -2.794, "52WeekChange": -0.11864406, "SandP52WeekChange": 0.19608545, "exchange": "NCM", "quoteType": "EQUITY", "symbol": "KPRX", "underlyingSymbol": "KPRX", "shortName": "Kiora Pharmaceuticals, Inc.", "longName": "Kiora Pharmaceuticals, Inc.", "firstTradeDateEpochUtc": 1423837800, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "0a06c299-968e-31d2-9678-be3e3334b429", "messageBoardId": "finmb_27817978", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.68, "targetHighPrice": 54.0, "targetLowPrice": 10.0, "targetMeanPrice": 30.33, "targetMedianPrice": 27.0, "recommendationMean": 1.7, "recommendationKey": "buy", "numberOfAnalystOpinions": 3, "totalCash": 31276330, "totalCashPerShare": 10.721, "ebitda": 6274047, "totalDebt": 94299, "quickRatio": 20.888, "currentRatio": 21.018, "totalRevenue": 16000000, "debtToEquity": 0.27, "revenuePerShare": 13.259, "returnOnAssets": 0.13201, "returnOnEquity": 0.124630004, "freeCashflow": 4164630, "operatingCashflow": 7137498, "grossMargins": 0.68235, "ebitdaMargins": 0.39213002, "operatingMargins": 0.82561994, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-07-25"}]